Trade MYGN anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Myriad Genetics, Inc. (MYGN) is trading at US$3.12, down 1.95% today as of Aug 28, 13:00 EDT. The company has a market capitalisation of US$306.08M. Over the past 52 weeks, MYGN has traded between US$2.74 and US$8.59. On Syfe you can trade MYGN with $0 commission and add it to your watchlist.
| Previous close | US$3.18 |
|---|---|
| Market cap | US$306.08M |
| 52-week range | US$2.74 – US$8.59 |
| Volume | 1.11M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Myriad Genetics, Inc.
Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Year: 1995
Myriad Genetics to Launch Prolaris + AI Prostate Cancer Test
May 26, 8:23 PM · MT Newswires
Myriad Genetics Secures Japanese Regulatory Approval For Prostate Cancer Diagnostic Test
Apr 14, 2:29 PM · MT Newswires
Myriad Genetics Gets US FDA Approval of MyChoice as Companion Diagnostic for Ovarian Cancer Drug
Mar 17, 8:56 PM · MT Newswires
Veracyte Appoints Kevin Haas as Chief Development and Technology Officer
Mar 16, 8:55 PM · MT Newswires
Myriad Genetics, Inc. (MYGN) stock is trading at US$3.12, -1.95% from the previous close of US$3.18.
The market cap for Myriad Genetics, Inc. (MYGN) stock is approximately US$306.08M.
The 52-week high for Myriad Genetics, Inc. (MYGN) stock is US$8.59.
The 52-week low for Myriad Genetics, Inc. (MYGN) stock is US$2.74.
Myriad Genetics, Inc. (MYGN) does not currently pay a dividend.
Stay on top of MYGN
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
